Mon - Fri 09:00 - 17:00 +61 3 7016 0801info@aeternahealth.com.au
Preventive Health
Advanced technology
Regenerative medicine technologies
Development and commercialization
Cellular Clinical Research
Innovation for medical practitioners

Advancing Immunotherapy: Aeterna Health at BEYOND EXPO 2024

1719205268 图片 20240524145528

On May 23rd, 2024, Aeterna Health was honored to participate in the BEYOND EXPO 2024 held in Macau, China. Our Chief Scientific Officer, Dr. Afsar Ahmed, delivered a compelling keynote presentation, showcasing our cutting-edge advancements in immune cell therapeutics.

Highlights from Dr. Afsar Ahmed’s Presentation

Emerging Trends in Immune Cell Therapy
Dr. Ahmed highlighted the rapid growth and potential of immune cell therapies, noting the significant increase in clinical trials, from 12 in 2012 to over 1200 currently. This exponential growth underscores the global interest and investment in these novel treatments.

Market Projections
The market for cancer immunotherapies is expected to expand significantly. For instance, the market value for CAR-T cell therapy, a type of immune cell therapy, is projected to grow from USD 7.5 billion in 2023 to USD 45 billion by 2033, reflecting a compound annual growth rate (CAGR) of 26.5%.

Challenges and Innovations
Despite the promise of immune cell therapies, challenges such as side effects, low efficacy against solid tumors, and lengthy manufacturing processes persist. Dr. Ahmed introduced our novel iCell technology, a new version of CAPRI cells, which addresses these issues by enhancing anti-cancer properties, reducing Th17 cells, and elevating central memory T cells.

Clinical Impact and Future Directions
Aeterna Health’s iCells have significantly improved patient outcomes, including increased survival rates in non-small cell lung cancer patients. Our ongoing research aims to extend these benefits to other cancers, autoimmune diseases, and immune-boosting applications.

Dr. Ahmed’s presentation underscored the need for a versatile and combinatorial approach to cancer immunotherapy. Our iCell technology, with its quick manufacturing process and physiological compatibility, is poised to meet the future demands of immune cell therapeutics.

Related Posts

Recent Papers

111719205789 AMcpdS Accreditation Badge ID 013446 General Practitioner 1 副本
Celebrating Aeterna Health’s Achievements in CPD Accreditation
24 June 2024
11Stem cell
Stem Cell Papers
13 April 2023

Scientific Excellence

Aeterna Health’s scientific excellence is supported by world-class experts in the field as well as cutting-edge cell biotechnology built on the platforms of top universities, hospitals and research institutes in Germany, Australia, China and the United States.